Close Menu

drug development

Syapse continues to help the FDA Oncology Center of Excellence incorporate real-world data into the regulatory decision-making process.

Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.

The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.

The Cold Spring Harbor Laboratory spinout will build predictive models for lung cancer progression and risk using its SpliceCore software platform.

The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.

The multi-omics translational software developer is helping the Crohn's & Colitis Foundation validate its research into biomarkers that can predict complications requiring surgery.

The company said it will use the financing to support the commercialization of its automated biological testing platform for academic and clinical research.

The Mayo Clinic Platform, now headed by John Halamka, will lean on Nference for multi-omics analytics to inform biomedical R&D and postmarketing surveillance.

By identifying core venom toxin genes with Indian cobra genomic and transcriptomic data, researchers hope to set the stage for future antivenom production based on synthetic venom.

The Chromium Connect, designed for pharma workflows and other high-volume customers, is one of several products coming out of 10x's R&D pipeline.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.